These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 9476114)

  • 21. [Complement activation and inflammation].
    Abe M
    Rinsho Byori; 2006 Jul; 54(7):744-56. PubMed ID: 16913666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decay-Accelerating Factor Creates an Organ-Protective Phenotype after Hemorrhage in Conscious Rats.
    Simovic MO; Falabella MJ; Le TD; DalleLucca JJ; Li Y
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complement factors and their receptors.
    Ember JA; Hugli TE
    Immunopharmacology; 1997 Dec; 38(1-2):3-15. PubMed ID: 9476110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis.
    Bosmann M; Ward PA
    Adv Exp Med Biol; 2012; 946():147-59. PubMed ID: 21948367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.
    Copland DA; Hussain K; Baalasubramanian S; Hughes TR; Morgan BP; Xu H; Dick AD; Nicholson LB
    Clin Exp Immunol; 2010 Mar; 159(3):303-14. PubMed ID: 20002447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies of therapeutic complement inhibition.
    Mollnes TE; Kirschfink M
    Mol Immunol; 2006 Jan; 43(1-2):107-21. PubMed ID: 16011851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.
    Weisman HF; Bartow T; Leppo MK; Marsh HC; Carson GR; Concino MF; Boyle MP; Roux KH; Weisfeldt ML; Fearon DT
    Science; 1990 Jul; 249(4965):146-51. PubMed ID: 2371562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibiting the C5-C5a receptor axis.
    Woodruff TM; Nandakumar KS; Tedesco F
    Mol Immunol; 2011 Aug; 48(14):1631-42. PubMed ID: 21549429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological effects of C1 inhibitor.
    Davis AE
    Drug News Perspect; 2004 Sep; 17(7):439-46. PubMed ID: 15514703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Complement inhibition: a new therapeutic modality?].
    Porcel JM
    Med Clin (Barc); 1995 Nov; 105(18):700-2. PubMed ID: 8538252
    [No Abstract]   [Full Text] [Related]  

  • 31. Complement inhibitory therapeutics and xenotransplantation.
    Ryan US
    Nat Med; 1995 Sep; 1(9):967-8. PubMed ID: 7585227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium.
    Weisman HF; Bartow T; Leppo MK; Boyle MP; Marsh HC; Carson GR; Roux KH; Weisfeldt ML; Fearon DT
    Trans Assoc Am Physicians; 1990; 103():64-72. PubMed ID: 2132543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complement: the Iceman of immunology?
    Würzner R
    Immunopharmacology; 1997 Dec; 38(1-2):63-4. PubMed ID: 9476115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation.
    Kroshus TJ; Rollins SA; Dalmasso AP; Elliott EA; Matis LA; Squinto SP; Bolman RM
    Transplantation; 1995 Dec; 60(11):1194-202. PubMed ID: 8525509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complement gene expression is regulated by pro-inflammatory cytokines and the anaphylatoxin C3a in human tenocytes.
    Busch C; Girke G; Kohl B; Stoll C; Lemke M; Krasnici S; Ertel W; Silawal S; John T; Schulze-Tanzil G
    Mol Immunol; 2013 Apr; 53(4):363-73. PubMed ID: 23070120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The future use of complement inhibitors for the treatment of neurological diseases.
    McGeer EG; McGeer PL
    Drugs; 1998 Jun; 55(6):739-46. PubMed ID: 9617589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The possibilities and pitfalls for anti-complement therapies in inflammatory diseases.
    Mizuno M; Morgan BP
    Curr Drug Targets Inflamm Allergy; 2004 Mar; 3(1):87-96. PubMed ID: 15032645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C1-inhibitor and transplantation.
    Kirschfink M
    Immunobiology; 2002 Sep; 205(4-5):534-41. PubMed ID: 12396013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anaphylatoxins in organ transplantation.
    Li K; Zhou W
    Semin Immunol; 2013 Feb; 25(1):20-8. PubMed ID: 23722015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of the complement system in the pathogenesis of multiple organ failure in shock.
    Zimmermann T; Laszik Z; Nagy S; Kaszaki J; Joo F
    Prog Clin Biol Res; 1989; 308():291-7. PubMed ID: 2675054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.